Abstract
Case report:
A 64 year-old female with Parkinson disease treated with amantadine for two years who suddenly suffered bilateral corneal oedema. It was initially treated as herpetic endotheliitis without improvement as we lacked information on her chronic treatment. The corneal oedema finally resolved after withdrawing the drug.
Discussion:
Amantadine hydrochloride may produce endothelial dysfunction. Once the amantadine treatment is stopped, the corneal oedema may be reversible but endothelial density remains low. An ophthalmologist examination should be performed before the initiation of amantadine treatment in order to establish a risk: benefit ratio, especially in those patients with low endothelial density or any endothelial anomaly.
Copyright © 2011 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Acyclovir / therapeutic use
-
Amantadine / adverse effects*
-
Amantadine / pharmacokinetics
-
Amantadine / therapeutic use
-
Antiparkinson Agents / adverse effects*
-
Antiparkinson Agents / pharmacokinetics
-
Antiparkinson Agents / therapeutic use
-
Aqueous Humor / metabolism
-
Cataract Extraction
-
Ceftazidime / therapeutic use
-
Corneal Edema / chemically induced*
-
Corneal Edema / drug therapy
-
Corneal Endothelial Cell Loss / chemically induced
-
Corneal Opacity / chemically induced*
-
Diagnostic Errors
-
Female
-
Humans
-
Keratitis / diagnosis
-
Middle Aged
-
Parkinson Disease / drug therapy*
-
Postoperative Complications / chemically induced
-
Prednisolone / therapeutic use
-
Saline Solution, Hypertonic / therapeutic use
-
Vancomycin / therapeutic use
Substances
-
Antiparkinson Agents
-
Saline Solution, Hypertonic
-
Vancomycin
-
Ceftazidime
-
Prednisolone
-
Amantadine
-
Acyclovir